Stockwinners Market Radar for October 30, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:49 EDT Microsoft says 'off to solid start' to FY25 - Says Azure Cloud took share in Q1. Says AI sales tracking to beat $10B run rate next quarter. Says nearly 70% of fortune 500 use Office AI tools. Says continues to take share across all major categories. Says "rapidly innovating." Comments taken from Q1 earnings conference call.

17:42 EDT Boise Cascade increases share repurchase authorization - Boise Cascade authorized the repurchase of an additional 1.4 million shares of common stock under its existing common stock repurchase program. From January 1 to October 30, the company repurchased 1.28 million shares of our common stock at a cost of approximately $165M. This authorization replenishes the existing common stock repurchase program, bringing the total repurchase authorization to approximately 2 million shares, which represents approximately 5% of shares outstanding.

17:36 EDT Sleep Number CEO says expected sequential improvement did not materialize - Says continuing to advance initiatives in gross margins and EBITDA to deliver on targets.

17:32 EDT Sleep Number CEO says need to be more efficient with media spend - Says advertising needs to have greater efficiency with less consumer in que to buy a mattress. Says seeing delayed decision making by consumers - seeing "some real hesitancy out there". Comments taken from Q3 earnings conference call.

17:32 EDT Roku says platform may not accelerate from current run rates in 2025 - Comment taken from Q3 earnings conference call. Shares of Roku are down 12.3% in after-hours trading.

17:29 EDT Cardiff Oncology publishes onvansertib combination data in journal - Cardiff Oncology announced the publication of data from its Phase 2 trial evaluating onvansertib in combination with Folfiri and bevacizumab for the second-line treatment of KRAS mutant metastatic colorectal cancer, or mCRC, in the peer-reviewed Journal of Clinical Oncology, the flagship publication of the American Society of Clinical Oncology, or ASCO. The results of the published Phase 2 clinical trial treating patients with KRAS-mutant mCRC demonstrated that onvansertib combined with FOLFIRI and bev was well-tolerated and revealed a greater clinical benefit in bev-naive patients compared to bev-exposed patients. In addition, the company showed the underpinnings of this clinical finding using preclinical models which demonstrated onvansertib inhibited the hypoxia pathway and exhibited robust antitumor activity in combination with bev through the inhibition of angiogenesis. Based on these findings, Cardiff Oncology initiated CRDF-004, a Phase 2 randomized clinical trial of onvansertib in combination with SoC for the first-line treatment of patients with RAS mutant mCRC. The company anticipates releasing initial data from the CRDF-004 trial in the second half of 2024.

17:25 EDT TopBuild to acquire Shannon Global Energy Solutions, terms undisclosed - TopBuild has entered into an agreement to acquire Shannon Global Energy Solutions, based in North Tonawanda, New York, with approximately $11M in annual revenue. Shannon Global, with a 36-year history, designs and fabricates reusable thermal, acoustical and safety products for many large multinational customers. The transaction is expected to close in the fourth quarter.

17:23 EDT CPS Technologies receives $12M contract - CPS Technologies announced that it has received an award, valued at approximately $12M, from a customer to provide power module components and related solutions. This agreement, though cancelable by either party, enables both parties to continue discussions about future volume and price requirements while near-term production needs are met. Deliveries are scheduled to take place over a twelve-month period starting in the current month, with volumes that represent a significant increase over the prior four quarters. The components will be employed primarily in high-speed rail, wind turbines and EV/HEV applications. The client company is a multinational semiconductor manufacturer based overseas.

17:17 EDT Starbucks sees fewer new store openings, renovations in FY25 - Says company's problems are "fixable," path forward is "clear." Says plans to bring back condiment bars by early next year. Says eliminating upcharge for non-dairy milks at North American cafes operated by Starbucks.

17:10 EDT Starbucks says Q4 traffic decline was mostly in the afternoon - Says frequency slowed across all SR membershipsSays in-store and out-of-store efficiency efforts delivered roughly 250 basis points of margin improvement for the full year, which is nearly $1B of cost reductions throughout PNL. Comments taken from Q4 earnings conference call.

17:05 EDT Micron Chair Robert Switz to retire, CEO Sanjay Mehrotra to succeed - Micron announced that Robert Switz, its current board chair, will retire at the annual shareholders meeting on January 16, 2025. The board has unanimously approved the appointment of Micron's president and CEO, Sanjay Mehrotra, to serve as board chair and Lynn Dugle as lead independent director following the annual shareholders meeting.

17:03 EDT Pebblebrook Hotel provides update on Hurricane Milton, other storms impact - Pebblebrook Hotel Trust provided an update regarding the impact of Hurricane Milton and other recent named storms on its properties, including the expected net financial impact. Except for LaPlaya Beach Resort & Club, all of the Company's southeast resorts are fully operational. LaPlaya, the 189-room luxury waterfront resort in Naples, Florida, is making significant strides in its restoration efforts following the impacts of Hurricane Helene on September 26, 2024, and Hurricane Milton on October 9, 2024. The Gulf Tower and the Bay Tower, along with BALEEN Naples, the resort's primary restaurant and bar, are all scheduled to reopen on November 1, 2024. LaPlaya's Beach House building remains closed for repairs primarily due to water and sand infiltration affecting ground-floor guestrooms. The resort's pools are also closed for temporary clean-up and repairs, with reopening expected in the near future. The Company currently anticipates that repair costs will not be material and expects that property, flood, and business interruption insurance, net of deductibles, will substantially mitigate the financial impact. Assuming normal and customary local approvals, the Company is currently estimating that the Beach House will reopen partially over the coming months and be largely operational by the end of Q1 2025. Pebblebrook's other resorts in southern Florida and Georgia remain fully operational and sustained no material property damage. However, these properties and LaPlaya experienced considerable cancellations and reduced booking volumes both before and following the storms, affecting operating performance in the third and fourth quarters. The most significant impact has been at LaPlaya. Please note that the Company continues to exclude LaPlaya from its Same-Property reporting due to LaPlaya's ongoing restoration following Hurricane Ian.

16:57 EDT Valero board executive chairman to retire - Valero Energy "announced that Joseph W. Gorder has chosen to retire as Executive Chairman and as a member of the Board effective as of the close of business on December 31, 2024. R. Lane Riggs, Valero's Chief Executive Officer and President, and member of the Board, has also been elected to the additional position of Chairman of the Board effective as of such date. Mr. Gorder retired as Valero's CEO effective as of the close of business on June 30, 2023 and has served as Executive Chairman of the Board since that time. In his role as Executive Chairman, Mr. Gorder has led the Board and continued to provide advice and counsel to the CEO and Valero's leadership on company decisions. Mr. Riggs has served as Valero's CEO and President, and member of the Board, since the close of business on June 30, 2023."

16:50 EDT Amarin sees current cash, investments, other assets to support operations - The Company is committed to executing against the significant opportunity in Europe. The Company is focused on maintaining market share in the U.S. and maximizing cash generation from the attractive and growing Rest of World RoW income stream. The Company continues to make progress on reducing operating expenses and managing its cash position, including $10 million of operating expense savings in the third quarter of 2024 compared to the third quarter of 2023. The Company reaffirms its belief that current cash and investments and other assets are adequate to support continuing operations for the foreseeable future.

16:48 EDT DoorDash, Lyft partner over exclusive benefits - DoorDash (DASH) and Lyft (LYFT) announced a partnership to offer benefits on both rides and local delivery. DashPass members will unlock monthly rideshare benefits at no additional cost, and eligible Lyft riders will receive a free trial of DashPass. Starting October 30, DashPass members and Lyft riders can receive exclusive monthly benefits to save on both services. "Since the launch of DashPass, we've been focused on building a membership program that provides tremendous value by helping people save on everything from restaurant meals to groceries to entertainment," said Prabir Adarkar, President and Chief Operating Officer at DoorDash. "Members enjoy $0 delivery fees, and get streaming with Max included at no additional cost with the DashPass Annual Plan. Our partnership with Lyft, a leader in the transportation space, gives DashPass members yet another way to save on the things that matter most to them."

16:47 EDT Warrior Met Coal affirms FY24 coal sales view of 7.4M-8.2M tons - Affirms FY24 coal production view of 7.4M-8.0M tons

16:44 EDT DoorDash sees Q4 adjusted EBITDA $525M-$575M - Sees Marketplace GOV $20.6B-$21.0B.

16:43 EDT Granite announced $42M P-928 Relay Ground Station project in Guam - Granite sitework and infrastructure project related to the Relay Ground Station-Asia (RGS-A) program at Naval Base Guam. Project funding is to come from federal sources and was included in Granite's third-quarter backlog. The project scope involves constructing four structures, multiple concrete foundations, and radar dome structures in support of the governments RGS-A program for the US space force. The RGS-A program is part of the U.S. Space Force's mission to update existing missile warning and missile defense systems with the Future Operationally Resilient Ground Evolution (FORGE) system. "The project offers a chance to work with a strong existing client and build a strategic relationship for future projects within the planned Guam Missile Defense System," said Curt Haldeman, Granite Vice President of Regional Operations. Design began in September 2024, with construction expected to start January 2025 and be completed in August 2026.

16:42 EDT Altair suspending quarterly, annual guidance - In light of the proposed transaction with Siemens, Altair is suspending quarterly financial results conference calls and its quarterly and annual guidance.

16:37 EDT Columbia Sportswear board approves $600M increase to buyback authorization

16:36 EDT Azenta receives regulatory approval for long-read WGS test - Azenta announced the launch of a long-read Whole Genome Sequencing test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. In contrast, Azenta's test makes use of PacBio's Revio sequencer to obtain long and highly accurate HiFi sequencing reads to cover regions that are inaccessible by short reads. Performed within GENEWIZ from Azenta Life Sciences CLIA certified and CAP accredited state-of-the-art clinical genomics laboratory, the test enables precise detection of a range of complex genomic alterations that are features of many rare diseases and undetectable by traditional approaches. This allows for a view of the genome with unprecedented comprehensiveness.

16:31 EDT LPL Financial expects to resume share repurchase program in Q4 - The company said, "We plan to resume our share repurchase program in Q4 2024, with an estimated $100 million of repurchases planned during the fourth quarter."

16:29 EDT Roku says advertising outperformed overall ad market and OTT ad market - The company states: "In Q3, the YoY growth of advertising activities across the Roku platform - excluding M&E (media & entertainment) - outperformed both the overall ad market and the OTT ad market in the U.S.9 The YoY growth of Political, Retail, and Consumer Packaged Goods ad verticals, among others, were up on the Roku platform, while the M&E and Health & Wellness ad verticals were pressured. Due to our many growth initiatives and focused efforts to diversify ad demand, M&E is a significantly smaller percentage of our overall Platform business now versus the last several years. We continue to leverage the power of our Home Screen to grow monetization and diversify revenue across ad verticals. The NBC Olympic Zone, featured on our Home Screen, was sponsored by leading brands across a diverse array of verticals including Retail, Transportation, Telecom, and Auto. In September, we partnered with the Television Academy to present The Emmys Collection, a dedicated destination for Emmy-nominated and winning titles. The collection was sponsored by a large specialty beauty retailer in the U.S. These viewer destinations drive engagement while broadening the sponsorship portfolio we offer to advertisers. As a result, ad spend on our Home Screen from non-M&E brands has grown in each of the last three quarters. We continue to drive new sources of ad demand. In Q3, we expanded our ad offering to better serve small and medium-sized businesses (SMBs). Roku Ads Manager is our new, self-service CTV advertising solution, providing performance features like advanced targeting, conversion optimization and measurement, and even shoppable ad formats. This solution builds upon our growing list of ad offerings that provide advertisers more choices for how they buy Roku Media - whether it be through direct IO (insertion order), a preferred DSP (demand-side platform) partner, or now through self service. This allows us to serve a diverse array of advertisers, across verticals and business-sizes, from SMBs to enterprise companies. We also continue to deepen our relationships with third-party platforms to better serve advertisers' programmatic needs. We have partnered with The Trade Desk (TTD) so that TTD customers can leverage Roku Media and audience data programmatically, and we have integrated Unified ID 2.0, TTD's identity solution. This represents our deepest integration to date with a third-party DSP, and we are beginning to see positive impacts. We'll continue to do more integrations that expand our ability to serve the entire demand curve at multiple price points and in doing so, we expect to drive incremental revenue over time."

16:27 EDT Altair Engineering trading halted, news pending

16:22 EDT Antero Midstream announces the addition of Munoz to board of directors - Paul Rady, Chairman and CEO said, "We are pleased to announce that Jeffrey Munoz has been appointed to the Board of Directors. Mr. Munoz has over 30 years of experience in the energy industry with legal and accounting expertise and will be a valuable addition to the Board."

16:15 EDT Pulse Biosciences names Kenigsberg as Chief Medical Officer of Electrophysiology - Pulse Biosciences announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter.

16:15 EDT Ryan Specialty maintains FY24 outlook for organic revenue growth at 13%-14% - Adjusted EBITDAC Margin guidance for full year 2024 is between 32.0% - 32.5%.

16:12 EDT Conmed names Patrick Beyer as new CEO - CONMED "announced that Curt R. Hartman will retire as President and CEO of the Company, effective January 1, 2025. Patrick Beyer, current Chief Operating Officer of CONMED, will succeed Mr. Hartman as President and CEO and will also be appointed as a member of the Company's board, effective the same date. As part of the transition, Lead Independent Director Martha Goldberg Aronson will assume the position of Chair of the Board on October 31, 2024, while Mr. Hartman will continue serving as a Director through December 31, 2024. Mr. Hartman will remain with CONMED as an advisor through March of 2027."

16:11 EDT Etsy sees Q4 adjusted EBITDA margin 28-29%

16:09 EDT Meta Platforms lowers FY24 total expense view to $96B-$98B - Meta said: "We expect full-year 2024 total expenses to be in the range of $96-98 billion, updated from our prior range of $96-99 billion. For Reality Labs, we continue to expect 2024 operating losses to increase meaningfully year-over-year due to our ongoing product development efforts and investments to further scale our ecosystem. We anticipate our full-year 2024 capital expenditures will be in the range of $38-40 billion, updated from our prior range of $37-40 billion. We continue to expect significant capital expenditures growth in 2025. Given this, along with the back-end weighted nature of our 2024 capital expenditures, we expect a significant acceleration in infrastructure expense growth next year as we recognize higher growth in depreciation and operating expenses of our expanded infrastructure fleet. Absent any changes to our tax landscape, we expect our fourth quarter 2024 tax rate to be in the low-teens."

16:08 EDT Meta Platforms reports family DAP of 3.29B on average for September, up 5% - Meta Platforms reports family daily active people, or DAP, was 3.29B on average for September 2024, an increase of 5% year-over-year. Ad impressions delivered across the Family of Apps increased by 7% year-over-year. Average price per ad increased by 11% year-over-year.

16:07 EDT Microsoft reports Xbox content and services revenue up 61% - Windows OEM and Devices revenue increased 2%. Xbox content and services revenue increased 61% driven by 53 points of net impact from the Activision acquisition. Search and news advertising revenue excluding traffic acquisition costs increased 18%. Revenue in More Personal Computing was $13.2 billion and increased 17%. Revenue in Intelligent Cloud was $24.1 billion and increased 20%. Revenue in Productivity and Business Processes was $28.3 billion and increased 12%. Microsoft 365 Commercial products and cloud services revenue increased 13%.

16:05 EDT Booking CEO says room night growth of 8% exceeded expectations - Glenn Fogel, Chief Executive Officer of Booking Holdings, said: "We are pleased to report third quarter room night growth of 8%, which exceeded our prior expectations, driven primarily by stronger performance in Europe. We continue to make progress against our strategic initiatives while driving cost efficiency in our business, which I believe will position our company well for the long term."

15:48 EDT CDC reports 15 new E. coli cases, says public risk 'very low' - The Centers for Disease Control and Prevention says fresh, slivered onions served on Quarter Pounders and other menu items from McDonald's are the likely source of the E. coli outbreak. "More illnesses have been reported but they are from before McDonald's and Taylor Farms took action to remove onions from food service locations," the agency said. "Due to the product actions taken by both companies, CDC believes the risk to the public is very low," " it added. The number of cases is now 90, with 15 new. There have been 27 hospitalizations, five new, and one death, which is not new.

14:31 EDT Ubisoft says workforce decreased by over 2,000 over last 24 months - Ubisoft said that its cost reduction plan, that has the objective of protecting our production and creation capacity while being more selective in our investments and simplifying the organization, is well on track. With the continued tight control on recruitments as well as targeted restructurings, the total number of employees worldwide stood at 18,666 at the end of September 2024, compared to 19,410 at the end of September 2023. This represents a decrease of more than 2,000 over 24 months. The H1 FY2024-25 fixed cost base stood at around EUR770M, down EUR46M and 6% year-onyear. This represents a EUR106M reduction versus H1 FY23 meaning that on an annualized basis, the company has already achieved more than EUR200M savings, including a favorable foreign exchange impact. There remains work ahead of us to support robust cash-flow generation.

12:53 EDT Airbus sees FY24 EBIT adjusted around EUR 5.5B - Sees around 770 commercial aircraft deliveries and Free Cash Flow before Customer Financing of around EUR 3.5B. As the basis for its 2024 guidance, the company assumes no additional disruptions to the world economy, air traffic, the supply chain, the company's internal operations, and its ability to deliver products and services.

12:37 EDT XCHG Ltd (ADR) trading halted, volatility trading pause

12:01 EDT Hims & Hers falls -14.6% - Hims & Hers is down -14.6%, or -$3.25 to $19.00.

12:01 EDT Garmin rises 24.4% - Garmin is up 24.4%, or $40.58 to $206.84.

12:00 EDT Reddit rises 40.6% - Reddit is up 40.6%, or $33.17 to $114.91.

11:46 EDT Boston Scientific presents ACURATE neo2 data at TCT 2024 - Boston Scientific Corporation announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2 Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery. The data were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation. This randomized trial evaluated the ACURATE neo2 valve, the company's second-generation transcatheter aortic valve replacement technology, versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system, selected at the discretion of the implanting physician. The composite rate of all-cause mortality, stroke or rehospitalization at one year was 16.16% in the ACURATE neo2 arm and 9.53% in the control arm, not meeting the prespecified criterion for non-inferiority. Also presented in the late-breaking session were data from a post-hoc analysis to identify and evaluate expanded and under-expanded ACURATE neo2 valve frames within the ACURATE IDE trial. The company performed a review of key procedural factors, including pre- and post-dilation, which helps to prepare for, enable and confirm proper valve expansion during the procedure. Following this review, an assessment of implant quality for the ACURATE neo2 valve was initiated and highlighted that approximately 20% of the valves were under-expanded. Data from the assessment also demonstrated that the rate for death, stroke or rehospitalization at one year was similar between the ACURATE neo2 expanded group and the control group. Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S.

11:26 EDT Dropbox to reduce workforce by approximately 20% - In an email to staff, CEO Drew Houston said, in part, "I'm writing to let you all know that after careful consideration, we've decided to reduce our global workforce by approximately 20% or 528 Dropboxers. As CEO, I take full responsibility for this decision and the circumstances that led to it, and I'm truly sorry to those impacted by this change...As we've shared over the last year, we're in a transitional period as a company. Our FSS business has matured, and we've been working to build our next phase of growth with products like Dash. However, navigating this transition while maintaining our current structure and investment levels is no longer sustainable. We continue to see softening demand and macro headwinds in our core business. But external factors are only part of the story. We've heard from many of you that our organizational structure has become overly complex, with excess layers of management slowing us down. And while I'm proud of the progress we've made in the last couple years, in some parts of the business, we're still not delivering at the level our customers deserve or performing in line with industry peers. So we're making more significant cuts in areas where we're over-invested or underperforming while designing a flatter, more efficient team structure overall...The changes we're making today, while difficult, come at a pivotal moment when the market is accelerating precisely where we've placed our biggest bets. It's been tremendously rewarding over the last few weeks to see customers and prospects light up when using Dash for Business for the first time, much like people did when we first launched Dropbox. And this time we're starting from a position of strength. Millions of customers trust us as the home for their most important files, making the leap to organizing all their cloud content a natural evolution." Reference Link

11:08 EDT Rackspace Technology signs multi-year collaboration agreement with AWS - Rackspace Technology (RXT) has signed a Strategic Collaboration Agreement with Amazon Web Services (AMZN), with plans to offer end-to-end cloud advisory, fin-ops, migration, modernization, cloud data, machine learning and generative AI solutions to accelerate customer value across their cloud adoption journey. The SCA includes a significant investment to help customers accelerate their migration and modernization initiatives for applications, data, and cloud infrastructure through the global expansion of the Rackspace Technology Migration and Modernization Center of Excellence. This builds on years of expertise working with the AWS Migration Acceleration Program. Rackspace Technology also recently announced the launch of Rackspace Rapid Migration Offer, which is designed to expedite data center migrations to AWS. RRMO, also available on AWS Marketplace, provides a comprehensive suite of services encompassing migration planning, landing zone setup, migration execution, and 24x7x365 cloud operations support with monitoring and incident response. Overall, the enhanced collaboration supports the delivery of business outcomes for customers globally from Rackspace's portfolio of full-stack cloud and AI services.

11:04 EDT Apple announces M4 Pro, M4 Max chips - Apple announced M4 Pro and M4 Max, two new chips that bring far more power-efficient performance and advanced capabilities to the Mac. All three chips are built using industry-leading, second-generation 3-nanometer technology, which improves performance and power efficiency. The CPUs across the M4 family feature the world's fastest CPU core, delivering the industry's best single-threaded performance, and dramatically faster multithreaded performance. The GPUs build on the breakthrough graphics architecture introduced in the previous generation, with faster cores and a 2x faster ray-tracing engine. M4 Pro and M4 Max enable Thunderbolt 5 for the Mac for the first time, and unified memory bandwidth is greatly increased, up to 75 percent. Combined with a Neural Engine that's up to 2x faster than the previous generation and enhanced machine learning accelerators in the CPUs, the M4 family of chips brings incredible performance for pro and AI workloads. And they deliver blazing performance for Apple Intelligence, the personal intelligence system that transforms how users work, communicate, and express themselves, while protecting their privacy.

10:56 EDT Connexa Sports Technologies Inc trading halted, volatility trading pause

10:41 EDT Wellchange Holdings Co Ltd trading resumes

10:36 EDT Wellchange Holdings Co Ltd trading halted, volatility trading pause

10:03 EDT Red River Bank selects Q2 to provide modern digital banking experience - Q2 Holdings (QTWO) announced Red River Bank (RRBI) has selected Q2 to deliver a cohesive digital banking experience for its consumer and commercial customers. Q2's digital banking platform will enable Red River Bank's consumer and commercial account holders to seamlessly conduct banking transactions across mobile and online banking.

10:00 EDT Garmin rises 19.2% - Garmin is up 19.2%, or $31.90 to $198.17.

10:00 EDT Reddit rises 33.9% - Reddit is up 33.9%, or $27.69 to $109.43.

10:00 EDT Eli Lilly falls -13.5% - Eli Lilly is down -13.5%, or -$121.82 to $781.76.

09:57 EDT Super Micro trading halted, volatility trading pause

09:49 EDT Baldwin Group drops 2% to $49.69 after Blue Orca short report

09:48 EDT Eli Lilly falls -12.0% - Eli Lilly is down -12.0%, or -$108.33 to $795.25.

09:47 EDT Unisys rises 14.9% - Unisys is up 14.9%, or 80c to $6.18.

09:47 EDT Reddit rises 32.1% - Reddit is up 32.1%, or $26.23 to $107.97.

09:40 EDT CRYO-CELL International, Inc. trading resumes

09:34 EDT AbbVie sees FY24 adjusted gross margin 84%

09:30 EDT CRYO-CELL International, Inc. trading halted, volatility trading pause

09:28 EDT VF Corp. introduces financial targets at investor day - VF Corporation is hosting its FY25 Investor Day, the first of a two-part investor event, and is introducing financial targets. The company introduced the following medium-term financial targets: adjusted operating margin of at least 10%; adjusted gross margin of at least 55%; adjusted SG&A as a percentage of revenue of 45% or lower and net leverage of 2.5x or below. Bracken Darrell, president and CEO, said: "We activated our transformation program, Reinvent, during my first 15 months at VF, through which we are making excellent progress advancing our priorities and reshaping the company. We are accelerating the pace of change by building new capabilities across our organization to leverage our powerful portfolio of brands for long-term, sustainable, profitable growth. We are beginning to see benefits from our initiatives, but significant upside remains as we create a structure primed for growth while transforming our company and its culture. This strong foundation positions us to quickly enhance VF's profitability while enabling further investment in sustainable shareholder value creation."

09:17 EDT Mullen Automotive's Bollinger Motors delivers B4 trucks to TEC Equipment - Mullen Automotive's Bollinger Motors has made its first customer delivery on the West Coast, sending three 2025 Bollinger B4 chassis cab electric trucks to TEC Equipment in Lacey, Washington, Fontana, California, and Oakland, California. Electronic payment has been received on the vehicles delivered, which have a retail value of approximately $500,000. Bollinger's revenue is being recognized in Mullen's current fiscal quarter ending December 2024.

09:16 EDT MultiSensor AI enters strategic channel partner relationship with IndustrAI - MultiSensor AI has entered into a formal strategic channel partner relationship with IndustrAI. MSAI and IndustrAI are working together closely to roll out MSAI's multi-sensor solution to a wide range of European customers. IndustrAI's base of industrial clients, and deep expertise with a range of industrial sensors make it an ideal partner for providing next-generation condition-based monitoring and predictive-maintenance solutions. IndustrAI also has long-standing European relationships with MSAI's warehouse and logistics launch customer and with Denali Advanced Integration, another of MSAI's strategic channel partners. These relationships will help MSAI scale faster and more efficiently with existing customers, provide better customer service, and expand into new industrial customers over time. In the medium term MSAI and IndustrAI plan to replicate this collaborative model in the Asia Pacific and Latin America markets. The strategic channel partnership arrangement goes into effect immediately and is expected to accelerate MSAI's European commercial activity significantly starting in the fourth quarter of fiscal 2024.

09:15 EDT Crexendo says Codefest drew 'record participation' - The company said, "Crexendo wrapped up its most successful Codefest to date as part of its annual User Group Meeting in Nashville, TN. The highly anticipated event saw unprecedented participation, with 16 groundbreaking entries from developers and partners showcasing innovative solutions built on Crexendo's NetSapiens Platform open API framework, focused heavily on AI-driven advancements and enhanced collaboration tools. The Annual Codefest served as a powerful demonstration of how developers are pushing the boundaries of innovation, enabling partners to create transformative solutions that harness the full potential of AI and next-generation technology. These solutions not only shape how businesses communicate and collaborate but are also designed to adapt seamlessly to the rapidly evolving landscape of modern enterprise needs. With a focus on driving real-world impact, the Codefest highlighted the commitment of developers and partners alike to build tools that are both cutting-edge and highly responsive to the demands of today's fast-paced, digital-first environment."

09:14 EDT WidePoint's IT Authorities awarded over $1.7M in contracts - WidePoint subsidiary IT Authorities has been awarded more than $1.7M in Cisco and Managed IT Services contracts. The contracts include Managed IT Services and Cisco solutions to: Three beverage distributors; A sports marketing firm; A child development and education outreach center; One of Florida's most popular attractions and research centers; A data management firm; A new Cisco Enterprise Agreement valued at $300,000 to be recognized in Q4 2024.

09:13 EDT Humana says has room for EPS progression

09:12 EDT Imunon to present Phase 2 data of IMNN-001 - IMUNON announced the acceptance of a late-breaking presentation featuring new clinical data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of advanced ovarian cancer, at the Society for Immunotherapy of Cancer, SITC, 39th Annual Meeting, being held November 6-10, 2024, in Houston, Texas and virtually. The company also announced plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration, FDA, in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in advanced ovarian cancer, with the trial expected to start in the first quarter of 2025.

09:10 EDT Fortinet announces general availability of FortiDLP solution - Fortinet announced the general availability of FortiDLP, a next-generation data loss prevention and insider risk management solution. Based on Next DLP's innovative technology and integration into the Fortinet Security Fabric, the new solution bolsters Fortinet's overall portfolio of DLP capabilities. FortiDLP enables effective management of data security, dynamic enforcement of data protection, and enhanced visibility of insider threats at scale for large enterprise customers.

09:10 EDT Hawkins expands water treatment footprint with acquisition of Water Guard - Hawkins has completed the acquisition of the assets of Water Guard. Water Guard distributes water treatment chemicals and equipment for its customers in Virgina and the Carolinas. "As we continue to grow our water treatment business, Water Guard brings us our first location in North Carolina and helps accelerate our expansion on the East Coast," said Hawkins Chief Executive Officer Patrick Hawkins. "Water Guard has built a strong business that we have admired for years and that is well-connected with the local community. We intend to maintain and expand those connections and look forward to a bright future together."

09:09 EDT Edible Garden completes additional product line at its Heartland facility - Edible Garden the successful completion of an additional production line at its Edible Garden Heartland facility in Grand Rapids, Michigan. This significantly boosts the facility's capacity, adding advanced processing capabilities to support the Company's produce and product lines.

09:07 EDT Humana says has 'work to do' in STARS

09:07 EDT AbbVie says performing 'exceptionally well' - Says "very focused" on investing in the business. Sees "numerous opportunities" to drive long-term growth. Comments taken from Q3 earnings conference call.

09:06 EDT Blink Charging awarded $2M grant to provide EV chargers for Illinois - Blink Charging has announced it has been awarded a nearly $2M grant to own and operate EV chargers for the state of Illinois. The grant, awarded by the Illinois Environmental Protection Agency, sets the stage for Blink Charging and Illinois to collaboratively help provide public charging solutions for employees, residents, and visitors.

09:06 EDT Appian expands partnership with the US Army - Appian announced an expansion of its ongoing partnership with the US Army as part of the Foreign Military Sales, or FMS, Army Case Execution System, or ACES, production delivery contract. The FMS-ACES contract has been awarded to Forge Group, with Appian as the platform provider. The solution combines the Appian Platform with AWS services available on cArmy. Horizon Industries, Limited and 540.co join the implementation team. Appian announces an expansion of its ongoing partnership with the US Army as part of the FMS-ACES contract.The FMS-ACES application will replace the Army's over 30-year-old Case Information System (CISIL). The Appian Platform will modernize and streamline the Army's FMS process, managing everything from case initiation and lifecycle management to case closeout, logistics, and financials. The application will provide Army users with automated workflow and process features, comprehensive data analysis and visualization capabilities, real-time connections to over 20 government data source systems, and detailed reporting capability.

09:05 EDT AstraZeneca reports China President currently under investigation - AstraZeneca stated: "Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities. Our China operations continue under the leadership of the current General Manager of AstraZeneca China. If requested, AstraZeneca will fully cooperate with the investigation."

09:05 EDT Digital Turbine to acquire ONE Store International - Digital Turbine and ONE Store, announce that Digital Turbine is acquiring ONE Store International, a subsidiary of ONE Store focused on global expansion. The acquisition of ONE Store International expands the partnership between the companies by bringing ONE Store's proven and robust alternative app store to key app growth markets in North America, the EU, and LATAM. The companies will leverage Digital Turbine's device footprint and SingleTap technology to enable frictionless app installs for developers who publish their apps on ONE Store, which already has 38 million users and nearly $1B in annual transactions. The companies are also collaborating on new technology and distribution capabilities to bring this expanded app store experience to iOS devices in the near future. As the partnership scales, Digital Turbine and ONE Store are committed to creating a comprehensive and competitive ecosystem beyond the traditional app store model, offering greater value to developers and consumers, and creating new opportunities for mobile operators to contribute to the ecosystem's growth.

09:04 EDT Nova Minerals provides quarterly activities report - Highlights: Estelle Gold Project: During the quarter Nova commenced and completed its 2024 Estelle drilling and surface exploration programs, with initial results received back from the laboratory in early October and more incoming. High-Grade Gold Continues at RPM: The 2024 drill program, which comprised of 21 holes and used the Company owned Reverse Circulation rig to keep costs to a minimum, was a highly targeted program focused on Pre-Feasibility stage drilling at the high-grade RPM deposit to continue to increase and prove-up resources to the higher confidence Measured and Indicated categories. The majority of the shallow drilling was allocated to advance the high-grade RPM starter pit area and to further delineate the at-surface, high-grade zone encountered there during the 2022-2023 drilling, while upgrading inferred resources and testing for potential near surface extensions of the high-grade gold system to the south and west. Initial results received in early October for the first 8 holes confirmed continuity of the near surface high-grade mineralization at RPM North with multiple broad intersections grading greater than 5 g/t Au from surface and sample interval grades up to 39 g/t Au. All holes ended in mineralization with highlight results including: RPMRC-24005: 43m @ 4.4 g/t Au from 2m, including 13m @ 10.7 g/t Au from 2m and 2m @ 39.2 g/t Au from 13m. RPMRC-24008: 45m @ 3.4 g/t Au from surface, including 131m @ 4.7 g/t Au from 3m and 8m @ 10.5 g/t Au from 22m. Extensive surface exploration sampling program was conducted around the wider RPM area to potentially extend existing and delineate additional high-grade mineralized zones, with results expected back in October. Antimony Discoveries Advanced: Stibium: Extensive surface exploration sampling program conducted at Stibium to follow up on the high-grade up to 60.5% Sb discovered in 2023 with results expected back in October. Massive stibnite, the primary ore mineral for antimony containing approximately 72% Sb, observed to be widespread in surface mapping and sampling at Stibium. 2,500kg bulk sample of a greater than2m wide quartz breccia vein ,where sample E408569 from 2023 returned 12.7 g/t Au and 2.1% Sb, collected at Stibium for metallurgical test work. Styx: Extensive surface exploration sampling program conducted at Syx to follow up on the high-grade up to 21.7% Sb discovered in 2023 with results expected back in October. Large vein containing massive stibnite in outcrop discovered at Styx; 500kg bulk sample of potential antimonious material containing stibnite collected from Styx for metallurgical test work. Test work to develop a process flow sheet and plant design in anticipation of a fast track standalone antimony production scenario at Stibium. Nova has submitted a proposal to the US Dept. Of Defense for potential grant funding to fast track Estelle's antimony production. Nova CEO Christopher Gerteisen, at the invitation of the US Dept. of Defense, attended another DoD related conference in September to discuss Estelle's near-term antimony production potential and illustrate how Nova could potentially help the US establish and fully secure domestic critical minerals supply chains. Another Extensive Surface Sampling Exploration Program Completed in 2024: Over 500 soil and 225 rock samples collected as part of the extensive 2024 surface exploration and mapping program targeting gold, antimony and other critical minerals from traverses at Stibium, Wombat, West Wing, Muddy Creek, RPM, Styx, and the new claims added in 2023. Assay results, which will be reported by area once received and processed, are expected back in October and November. Estelle Staged Development Optionality: Estelle is a major mineralized trend, hosting gold, antimony, silver, copper, and other critical elements and Nova is working to begin production as early as possible with the potential to operate for decades supplying the minerals the world needs. The Pre-Feasibility Study currently underway is considering a strategy to achieve production as soon as possible with a scalable operation, subject to market conditions and strategic partners, by; Establishing an initial lower capex smaller scale operation at the high-grade RPM deposit for potential near term cashflow at high margins to self-fund expansion plans; and/or Develop the higher capex larger mining operation with increased gold production, cash flow, and mine life, which is of interest to potential future large gold company strategic partners. With China announcing export restrictions on antimony, the Company is also investigating the possibility to fast track the Stibium gold-antimony prospect development option with potential US Dept. of Defense support. Environmental studies progressing and Lidar survey completed for detailed technical studies, infrastructure, and access road design.

09:03 EDT Unity announces Steve Collins as CTO - Unity announced Steve Collins will join Unity as CTO, adding technical leadership to accelerate product innovation, quality, and stability. Collins brings decades of experience from his tenure as CTO at King, the studio behind Candy Crush, and as co-founder and CTO of Havok.

08:58 EDT Assurant announces heavy truck extended service contract - Assurant introduced the Assurant Heavy Truck Extended Service Contract. This new protection solution for Class 8 trucks offers a comprehensive suite of coverage options, including roadside assistance and towing, allowing dealers of new and used heavy trucks to offer their customers protection that can reduce total ownership costs, minimize downtime, and get them back on the road quickly.

08:52 EDT Roadzen unveils Mixtape AI platform - Roadzen has launched MixtapeAI, a platform designed to power AI agents and transform customer interactions in the insurance and mobility sectors. With MixtapeAI, insurers, brokers, agents, carmakers, and fleets can deliver intelligent, personalized, and secure customer experiences while automating complex workflows across multiple touchpoints. The company said, " MixtapeAI leverages best-in-class foundation models such as OpenAI, Google, Anthropic, and Meta, ensuring customers receive natural, intelligent responses. Specifically tailored for the insurance and mobility sectors, MixtapeAI empowers businesses to: Automate Complex Workflows, Resolving Issues from Start to Finish. From KYC and claims processing to policy administration and roadside assistance, MixtapeAI agents handle entire workflows autonomously, including complex cases, providing a comprehensive end-to-end solution. Engage with Customers Across Channels. With multi-modal capabilities, MixtapeAI can connect with customers on chat, email, phone, social media, and more, ensuring smooth, consistent interactions at every touchpoint."

08:48 EDT AnaptysBio sinks 30% after Lilly slides show PD-1 agonist pulled - Shares of AnaptysBio (ANAB) are plummeting after earnings slides from Eli Lilly (LLY) showed the company removed peresolimab, a PD-1 agonist, from its mid-stage pipeline. AnaptysBio is developing its own PD-1 agonist, rosnilimab. The shares in premarket trading are down 31%, or $9.44, to $21.69.

08:46 EDT Itron unveils CityEdge Portfolio to address modern city challenges - Itron is unveiling its CityEdge portfolio, which brings together IoT technologies to solve real-city challenges, while preparing cities for the future. With CityEdge, Itron is rebranding its proven smart city and smart lighting solutions and providing an open, flexible platform upon which cities can build. CityEdge addresses challenges and opportunities in five fundamental areas within the city and municipal space: smart lighting; traffic and highways; environment and sustainability; public safety; and energy, water and utilities. Itron will showcase the CityEdge portfolio at the upcoming Smart City Expo World Congress in Barcelona, Spain, from Nov. 5-7, 2024.

08:45 EDT LQR House announces marketing partnership with Region de Mexico Tequila - LQR House announced a new marketing collaboration with Region de Mexico Tequila. This partnership aims to drive brand awareness and its sales on CWSpirits.com through a multi-channel campaign, including social media, influencer partnerships, email and SMS blasts, and homepage banners on the platform. Additionally, Region de Mexico Tequila will be prominently featured in LQR House's Holiday Gift Guide, capitalizing on what LQR House views as the most important sales season in the alcohol industry.

08:43 EDT Twin Vee PowerCats launches 'CEO Hustle' webcast - Twin Vee PowerCats launched its new webcast series, "CEO Hustle," with two videos hosted by CEO Joseph Visconti. CEO Hustle is posted regularly on Joseph's social media accounts and YouTube channel, ensuring convenient access for individuals who prefer to consume content on their platform of choice. Announced last week, the series provides a behind-the-scenes look at Twin Vee and its manufacturing operations in Fort Pierce, Florida, where viewers can explore production processes, learn about the Company's latest boat models and news, and meet members of Twin Vee's dedicated team.

08:41 EDT CytoDyn appoints Melissa Palmer as lead consultant in hepatology - CytoDyn announced that Dr. Melissa Palmer, M.D., has been engaged as Lead Consultant in Hepatology. In this role, Dr. Palmer will drive the Company's strategy for research and development in Hepatology, leveraging her expertise to further CytoDyn's clinical evaluation of leronlimab in treating liver conditions, including MASH and liver fibrosis. This engagement follows the recent breakthroughs with SMC Laboratories. In addition, the Company announced that following initial results from its preclinical study with SMC, it has commissioned the lab to conduct two follow-up studies to confirm and extend the observation of fibrosis reversal observed in the study concluded in September 2024. Both follow-up studies are underway, with results expected in early 2025. Palmer brings more than three decades of deep research experience to the CytoDyn team. She has held leadership positions at several biotech and pharmaceutical companies, including serving as CMO of Gannex/Ascletis and Head of Liver Disease at Takeda Pharmaceutical Company. Dr. Palmer will work with the CytoDyn team to oversee the two follow-up studies with SMC. These studies will again compare leronlimab alone and in combination with other therapies, including both resmetirom, the only approved treatment for MASH, and a GLP-1 agonist in an increased number of mice evaluated in both a proprietary STAM model of MASH which includes T2DM, as well as a second model of liver fibrosis driven by CCL4 toxicity that is independent of fat deposition.

08:40 EDT Wipro, Microsoft and SAP team on RISE with SAP migration - Wipro Limited (WIT) announced a strategic collaboration with Microsoft (MSFT) and SAP (SAP). The initiative is designed to help clients significantly improve the speed and effectiveness of RISE with SAP migrations on the Microsoft Cloud. Through the collaboration, Wipro will be able to offer clients a strategic roadmap and best practices to fully harness the potential of RISE with SAP, enhancing digital operations, overall efficiency, and improved customer experiences. The joint effort also includes financial incentives that allow clients to achieve a 'Near Zero Cost Migration' on their way to becoming an intelligent enterprise. "We are excited to announce our pioneering collaboration with Microsoft and SAP," said Srinivas Sai Nidadhavolu, Vice President and Global SAP Practice Leader, Wipro Limited. "By leveraging our industry-leading digital capabilities, together with the expertise of partners, we are well positioned to accelerate our clients' transformation into intelligent enterprises, driving them towards sustainable growth."

08:39 EDT Ageagle Aerial Systems appoints Lowdermilk to board of directors - AgEagle Aerial Systems announces the appointment of Kevin Lowdermilk to the Company's board of directors effective October 25, 2024. Kevin Lowdermilk has over 30 years of executive leadership experience and currently serves as both the CEO and CFO of Vaya Space.

08:38 EDT Lockheed Martin completes Terran Orbital acquisition - Lockheed Martin has completed its previously announced acquisition of Terran Orbital, a manufacturer of innovative modular spacecraft serving the global aerospace and defense industries, and its subsidiary, Tyvak International. Lockheed Martin has worked with Terran Orbital on projects including Space Development Agency programs and Lockheed Martin's technology demonstrations. Reporting through Lockheed Martin's Space business area, the company will be recognized as Terran Orbital, a Lockheed Martin Company. It will remain a merchant supplier to the industry and bring holistic solutions by coalescing satellite design, production, launch planning, mission operations, and in-orbit support to meet the needs of the most demanding military, civil, and commercial customers' missions.

08:37 EDT FDA awards grant to validate in vitro-in vivo extrapolation to Simulations Plus - Simulations Plus announced a newly funded grant from the U.S. Food and Drug Administration FDA , secured in partnership with the University of Strathclyde and InnoGI Technologies. The project is expected to improve the understanding of amorphous solid dispersion ASD formulations in different conditions and predict the impact of food and pH-dependent drug-drug interactions DDIs through the combination of novel in vitro testing and mechanistic modeling and simulation. For this award, Professor Hannah Batchelor, through her lab at the University of Strathclyde, will analyze ASD drug products and their respective formulation variants. InnoGI Technologies will then test the different ASD formulations under fasted, fed, and higher gastric pH conditions utilizing the tiny-TIMsg, part of the SurroGUT Platform, in vitro system. Next, physiologically based pharmacokinetic PBPK models will be developed in the GastroPlus platform to link in vitro dissolution with in vivo pharmacokinetic data and develop in vitro-in vivo extrapolations IVIVEs . Finally, virtual bioequivalence VBE trial simulations will be conducted in GastroPlus to assess the clinical performance of ASD formulation variants to validate the approaches. The resulting outcomes are anticipated to help speed up formulation adjustments, reduce costs, and accelerate time-to-market for both innovator and generic ASD products. "We are delighted to be at the forefront of this important research, which has the potential to significantly advance PBPK science and revolutionize how we predict drug product performance," said Dr. Maxime Le Merdy, Director of PBPK Collaborations at Simulations Plus and principal investigator for this grant. "Developing a novel IVIVE methodology for ASD drug products will play a crucial role in optimizing formulation development, fine-tuning process parameters, and supporting bioequivalence assessments by offering key insights into the factors that impact in vivo performance." FDA scientific and program staff will actively collaborate with the University of Strathclyde, InnoGI Technologies, and Simulations Plus. Dr. Le Merdy, with assistance from scientists at Simulations Plus, will coordinate the modeling and simulation activities of the contract.

08:36 EDT Brand Engagement Network agrees to acquire 100% of Cataneo - Brand Engagement Network announced it has agreed to acquire 100% of Cataneo, a privately-owned media technology company based in Munich, Germany, in a cash and stock transaction. Cataneo offers an all-in-one solution for ad sales, inventory management, and campaign optimization. The company has been profitable throughout the years, with its platform helping broadcast and entertainment companies streamline operations, increase revenue, and enhance audience engagement. By integrating BEN's advanced Generative AI, Cataneo is poised to strengthen its offerings and deliver even greater value to its brands and customers.

08:35 EDT HeartCore expands its CMS platform offering into SaaS delivery model - HeartCore Enterprises (HTCR) announced it has expanded its flagship CMS platform to include a Software as a Service, SaaS, model, in addition to its legacy on-premises version. As part of this transition, HeartCore will leverage the Amazon (AMZN) Web Services infrastructure and collaborate with the AWS team to enhance the product's foundational capabilities. This includes a redesigned user interface and a comprehensive overhaul of the Management Screen Builder to enhance accessibility and allow users to update and manage multiple sites seamlessly, eliminating the need for specialized developer skills. HeartCore will expand its target audience to include businesses that require CMS solutions delivered through a SaaS model, a segment previously beyond reach.

08:34 EDT Tiziana Life Sciences announces results from ozempic, nasal anti-CD3 study - Tiziana Life Sciences (TLSA) announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NVO) under the brand names Ozempic and Wegovy. The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity, providing a potential novel approach to combat obesity-related inflammation, and liver inflammation and dysfunction. Key Highlights: Nasal anti-CD3 in combination with semaglutide demonstrates synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity. The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders.

08:33 EDT Charles Schwab to pilot additional access to overnight trading session - Charles Schwab announced it will begin piloting additional access to the overnight trading session by expanding to include stocks in the S&P 500, Nasdaq-100 and hundreds of additional exchange-traded funds, or ETFs, available for trading 24 hours a day, five days a week. Ameritrade, which was acquired by Schwab in 2020, introduced 24/5 trading in 2018 when it was the first U.S. retail broker-dealer to make it available to traders. Since then, clients using the thinkorswim trading platforms at Ameritrade and now Schwab have had access to approximately two dozen ETFs in the overnight trading session. Schwab will begin piloting expanded overnight access with a small group of clients and gradually expand to full client access in 2025.

08:33 EDT DarioHealth signs new regional health plan - DarioHealth announced a new contract with a regional health plan in the Medicaid space, which has launched with the full suite of cardiometabolic solutions. The launch with this new health plan marks the third Medicaid client for Dario, continuing a solid momentum within the Medicaid space. The newly signed health plan, familiar with Dario's results with another regional health plan, chose Dario based on the Company's success and reputation for driving engagement among diverse populations. Dario's ability to drive highly personalized member experiences across a wide range of channels and support modalities is attractive to Medicaid plans managing members with limited access to traditional channels. Starting with an initial pilot program, Dario will work closely with the health plan to bring its proven solutions to the plan's population, which includes nearly 10,000 Medicaid members.

08:32 EDT Sabre and TAP Air Portugal sign distribution agreement - Sabre and TAP Air Portugal, the main Portuguese airline, announced an expanded distribution agreement. Sabre-connected travel agents can immediately start placing activation requests for NDC offers. Once activated, they can book TAP Air Portugal evolving NDC offers alongside the airline's traditional EDIFACT content. Sabre-connected travel agents can start placing activation requests to shop, book, and service TAP Air Portugal's NDC offers. These offers will sit alongside traditional content in Sabre's travel marketplace, providing travel agents with a comprehensive range of options to best serve their customers. Travel agents will be able to access this content through Sabre's Offer and Order APIs, the agency point-of-sale solution, Sabre Red 360, and the corporate booking tool, GetThere.

08:29 EDT Amdocs introduces next generation of fiber offering - Amdocs announced the next generation of its fiber offering, capitalizing on recent acquisitions in the fiber domain. The enhanced offering introduces a robust framework and advanced automation capabilities to accelerate the planning, design, deployment and operation of fiber networks, yielding more cost-effective deployment for global service providers. The company said, "Amdocs has established itself as an industry leader in simplifying and speeding the deployment and management of fiber for more than 40 leading service providers around the world, with: A proven track record of designing over 1.2 million fiber route miles globally A large team of experts, leveraging modern program management tools to deliver faster deployments and maintain accountability throughout the process Superior performance, integrating AI and generative AI-driven automation and real-time decisioning in business and operations support systems, processes and network assurance, to improve customer service efficiency A newly formed teaming agreement with IQGeo, a developer of geospatial network lifecycle management software for telecom and utility operators, further enhances these capabilities. Amdocs will integrate IQGeo's network management software into its offering, enabling service providers to visualize, update, and manage their network assets in real time, and to automate key aspects of the planning and design process, driving faster deployment times and reducing the complexity of managing large-scale fiber projects. Selected benefits for service providers include: 30% faster deployment times for fiber rollouts Reduction of cabling and trenching by 10% or more Significant reduction in network management cost by seamlessly integrating existing systems, replacing manual processes and reducing errors & rework Amdocs' fiber offering will provide zero-touch automation capabilities that streamline complex fiber deployment processes. Service providers will benefit from a unified, future-ready solution that supports both greenfield and brownfield deployments, allowing them to optimize time to market, reduce operational costs, and improve overall network performance."

08:27 EDT Wingstop reports Q3 domestic SSS up 20.9% - In Q3: System-wide sales increased 39.4% to $1.2B; 106 net new openings; Domestic restaurant AUV increased to $2.1M; Domestic same store sales increased 20.9%; Digital sales increased to 69.0% of system-wide sales.

08:20 EDT Asante Gold announces $525M financing package - Asante Gold provided an update on a planned financing package of $525 million to fully fund its growth plans and recapitalize its short-term liabilities. The Financing Package is planned in two stages and is expected to include the previously announced $100 million equity private placement plus $425 million of additional financing transactions, including a comprehensive refinancing agreement with Kinross Gold Corporation, issuance of senior debt, Ghanaian bond and gold stream agreements. HIGHLIGHTS: Financing Package of $525 million to fully fund growth plans and balance sheet needs, including: Bibiani: pit expansion, sulphide plant, community resettlement, underground mine development Chirano: mobile equipment, underground development and expansion, plant upgrades Kinross: refinancing to include equity conversion and deferral of amounts owed Settlement of other short-term liabilities Stage 1: $325 million in financing expected to be completed by the end of 2024, including: $100 million equity private placement, as previously announced $100 million Kinross Refinancing, including increased shareholding in Asante to 9.9% $75 million local currency, dollar-linked bond funded by strategic Ghanaian institutions $50 million syndicated gold stream facility Stage 2: $200 million in financing expected to be completed in early 2025, including: $150 million senior debt facility, to be arranged by FirstRand Bank Limited as Initial Mandated Lead Arranger and Bookrunner $50 million standby equity commitment from a strategic investor Endeavour Financial is acting as the Company's financial advisor in connection with the Financing Package. Completion of the transactions disclosed in this news release remain subject to, among other things, the negotiation and execution of definitive agreements, the completion of satisfactory due diligence by certain counterparties, and receipt of requisite stock exchange approvals.

08:20 EDT Biomerica announces direct-to-consumer availability of inFoods IBS test - Biomerica announce a major enhancement to its inFoods IBS platform. US consumers can now order the inFoods IBS test directly from infoodsibs.com and consequently collect a sample in the comfort of their home. As part of this ordering process, a licensed physician remotely authorizes the test, ensuring professional medical oversight, without the need for visiting a doctor's office.

08:18 EDT Navient repurchased 2.1M shares in Q3, sees doubling that amount in Q4

08:17 EDT DatChat subsidiary Dragon Interact acquires RPM Interactive - Dragon Interact, a subsidiary of DatChat, announces the acquisition of RPM Interactive in a share exchange transaction. Pursuant to the agreement, Dragon Interact acquired 100% ownership of RPM Interactive, including all of its intellectual property, in consideration for the issuance of 3.5 million shares of common stock. As part of the acquisition, Dragon Interact plans to change its corporate name to RPM Interactive, reflecting its new focus on cutting-edge AI-driven podcast and gaming technologies.

08:14 EDT American Rebel expands distribution network to Commonwealth of Kentucky - American Rebel Holdings entered an agreement in the Commonwealth of Kentucky with premier distributor Clark Distributing Company to distribute American Rebel Light Lager - America's Patriotic Beer. "We are excited to enter the Kentucky market with Clark Distributing Company," said Andy Ross, Chief Executive Officer of American Rebel. "Clark Distributing Company is an institution in the state of Kentucky and adding them to our distributor roster will make American Rebel Beer available in another key state within our targeted expansion across this patriotic, God-fearing country of ours."

08:13 EDT Nano Nuclear Energy closes full over-allotment option raising $40M in funds - NANO Nuclear Energy announced the October 29, 2024 closing of the sale of an additional 317,646 shares of its common stock at $17.00 per share pursuant to the full exercise of underwriter's over-allotment option granted in connection with NANO Nuclear's recent underwritten follow-on public offering which closed on October 25, 2024. The gross proceeds from this public offering, inclusive of the full over-allotment exercise, before deducting underwriting discounts and other offering expenses, were approximately $41.4 million, and net proceeds were approximately $37.7 million. The Benchmark Company, LLC acted as the sole book-running representative for the offering. Ellenoff Grossman & Schole LLP acted as counsel to NANO Nuclear. Lucosky Brookman LLP acted as counsel to The Benchmark Company. Withum Smith+Brown PC are NANO Nuclear's registered independent auditors.

08:12 EDT Can B Corp. announces holding company reorganization with Nascent Pharma - Can B Corp. has implemented a reorganization in which a new holding company, Nascent Pharma Holdings, Inc., has become the publicly-traded parent of Can B and its subsidiaries. As a result of the reorganization, existing shares of Can B stock have been automatically converted, on a one-for-one basis, into shares of common stock of Nascent Pharma Holdings, Inc. The Board and executive officers of Can B will continue in the same roles at Nascent Pharma Holdings, Inc. In March 2024, Can B announced that it had shifted its primary focus to protecting and commercializing the cannabis patents acquired by its 67% owned subsidiary, Nascent Pharma, LLC, in February 2024. Can B believes that the reorganization will enhance its ability to raise capital to fund future business opportunities, including partnerships. licensing agreements, and potential litigation funding to support Nascent's patent protection efforts. The change in the name of the publicly traded name and the issuance of a new trading symbol is currently being processed by FINRA. Shares of the publicly traded company will continue to trade under the symbol "CANB" until the processing of the name change is complete and the new trading symbol is issued.

08:10 EDT Grace Therapeutics to host virtual KOL event on GTX-104 - Grace Therapeutics will host a virtual key opinion leader event on Wednesday, November 20, 2024 at 2:00 PM ET. The event will feature Abhishek Ray, MD and Andrew Webb, PharmD, BCCCP, who will discuss the high unmet medical need and current treatment landscape for patients suffering from aneurysmal Subarachnoid Hemorrhage, a rare and life-threatening medical emergency.

08:10 EDT Leidos awarded $93M contract to support Navy, Marine Corps weapons systems - Leidos announced a new contract to provide critical supply support for weapons systems that keep the U.S. Navy and Marine Corps forces mission-ready. The Technical Assistance for Repairables Processing contract was awarded by the Naval Supply Systems Command Fleet Logistics Center, supporting NAVSUP's Weapon Systems Support. The contract has a base period of performance of one year with four one-year options and one six-month option.

08:08 EDT Mineralys completes enrollment ahead of schedule in Launch-HTN trial - Mineralys Therapeutics has completed enrollment in the Launch-HTN trial ahead of schedule. Launch-HTN is the second of two trials under the planned pivotal program evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension. The Company expects the trial to be completed earlier than planned, with topline data now anticipated in mid first half of 2025. The Launch-HTN trial, a global, randomized, double-blinded, placebo-controlled Phase 3 trial, enrolled eligible adult participants who failed to achieve their blood pressure goal despite being on two to five background antihypertensive medications. Eligible subjects were randomized to one of three arms: placebo, lorundrostat 50 mg once daily, and lorundrostat 50 mg QD and then titrated to 100 mg QD, as needed, at week six. The primary endpoint of the trial is change from baseline in systolic blood pressure versus placebo after six weeks of treatment, as measured by automated office blood pressure monitoring.

08:06 EDT Cerence, Renault partner to bring generative AI to Reno - Cerence (CRNC) announced its expanded partnership with Renault (RNLSY) to bring generative AI-powered capabilities and human-like interaction to the automaker's next-generation, multi-modal in-car companion, Reno. Reno, the official Renault avatar, is an intelligent, helpful, and endearing in-car companion that brings customers a more intuitive and fun driving experience. Expanding on Renault and Cerence's multi-year partnership to bring Reno to life with humanized, voice-powered interaction, Renault will now leverage generative AI-powered Cerence Chat Pro to advance Reno's capabilities and bring Reno's intelligence to an entirely new level. Cerence Chat Pro, a uniquely intelligent, automotive-grade large language model integration, will enable Renault customers to engage Reno in fun and conversational chit-chat, leveraging a multitude of sources, including ChatGPT, to provide accurate and relevant responses to nearly every query imaginable.

08:06 EDT Avidity begins a biomarker cohort in the Phase 1/2 FORTITUDE trial - Avidity Biosciences announced the initiation of a biomarker cohort in the Phase 1/2 FORTITUDE trial of delpacibart braxlosiran in people living with facioscapulohumeral muscular dystrophy, or FSHD. Avidity is pursuing a potential accelerated approval path for del-brax and expects enrollment in the biomarker cohort to be completed in the first half of 2025. Avidity also remains on track to initiate a functional cohort in the first half of 2025. In addition, enrollment of the FORTITUDE Open-label Extension study, or OLE, is ongoing. Del-brax is the first investigational therapy designed to treat the underlying cause of FSHD by directly targeting the disease-causing gene, double homeobox 4. Currently, there are no approved therapies for the treatment of FSHD, a rare, hereditary disorder marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability. The biomarker cohort in the FORTITUDE trial will assess the impact of del-brax 2 mg/kg every six weeks in people living with FSHD, ages 16-70. The primary endpoints of the study are changes in DUX4 regulated gene expression and DUX4 regulated circulating biomarker.

08:05 EDT Meritage Homes announces acquisition of assets of Elliott Homes - Meritage Homes announced its entry into the Gulf Coast markets through the acquisition of the assets of Elliott Homes. Elliott Homes is a top five Gulf Coast homebuilder with operations in Mississippi, Alabama and the Florida panhandle. With this acquisition, Meritage will acquire over 5,500 lots and expects to commence production operations in existing entry-level communities before the end of the year, with a meaningful contribution from these operations in 2025.

07:56 EDT Global Payments to sell AdvancedMD, terms undisclosed - Francisco Partners announced it has signed a definitive agreement to acquire AdvancedMD from Global Payments. Global Payments will continue to power the company's payment acceptance capabilities as a long-term partner ensuring consistency of delivery and a seamless transition for employees and customers. The acquisition is expected to close in the fourth quarter of 2024, subject to the satisfaction of customary closing conditions.

07:50 EDT Critical Elements Lithium engages ICP Securities for market making serices - Critical Elements Lithium has engaged the services of ICP Securities to provide automated market making services, including use of its proprietary algorithm, ICP Premium, in compliance with the policies and guidelines of the TSXV and other applicable legislation. ICP will be paid a monthly fee of $7,500, plus applicable taxes. The agreement between the Corporation and ICP was signed with a start date of October 29, 2024, and is for four months and shall be automatically renewed for subsequent one month terms unless either party provides at least thirty days written notice prior to the end of the Initial Term or an Additional Term, as applicable. There are no performance factors contained in the agreement and no stock options or other compensation in connection with the engagement. ICP and its clients may acquire an interest in the securities of the Company in the future. ICP is an arm's length party to the Corporation. ICP's market making activity will be primarily to correct temporary imbalances in the supply and demand of the Corporation's shares. ICP will be responsible for the costs it incurs in buying and selling the Corporation's shares, and no third party will be providing funds or securities for the market making activities.

07:47 EDT Jeffs' Brands enters non-binding LOI for sale of Smart Repair Pro subsidiary - Jeffs' Brands has entered into a non-binding letter of intent for the sale of its subsidiary Smart Repair Pro, which operates Jeffs' Brands' stores on the U.S. Amazon Marketplace, marking a strategic shift in the Company's global focus. Following the completion of the Transaction, Smart Repair Pro will be held by a separate U.S. public company, traded on the OTC pink sheets, at a valuation of approximately $13.125 million for Smart Repair Pro. Under the terms of the LOI, Jeffs' Brands will transfer all the shares of Smart Repair Pro to the Acquiring Company, in exchange for 75% of the Acquiring Company's issued and outstanding shares as the base payment upon closing of the Transaction. Upon the achievement of certain milestones, including the uplisting of the Acquiring Company to a national U.S. exchange within three years from the closing of the Transaction, Jeffs' Brands will receive an additional 15% equity stake in the Acquiring Company, as a deferred payment. The Transaction reflects a valuation of approximately $1.5 million for the Acquiring Company, taking into account the completion of the deferred payment and contingent on cash holdings of at least $750,000. With this strategic Transaction, Jeffs' Brands aims to sharpen its focus on core markets while retaining significant ownership in the future growth of its U.S. operations. The Transaction is expected to close by December 31, 2024, subject to the successful completion of due diligence by both parties, the execution of binding definitive agreements with respect to the Transaction, which shall include customary closing conditions, and compliance with any regulatory approvals. There is no guarantee when or if the Transaction will be completed.

07:45 EDT Datametrex announces Imagine Health Centres resumes accepting new patients - Datametrex AI announced that its Imagine Health Centres clinics in Calgary and Edmonton resumed accepting new patients, supported by the addition of several new physicians across both locations. For new patients interested in accessing care, the Company encourages patients to contact each clinic directly. The Calgary clinic has welcomed an expanded team of physicians to meet the needs of the community. Dr. Matthew Kerslake, a walk-in physician and Certified PrEP Prescriber, is available Monday through Thursday from 9:00 AM to 5:00 PM, providing consistent walk-in care throughout the week. Dr. John Haddad and Dr. Ingrid Cheung offer additional walk-in support, with Dr. Haddad available on Tuesdays and Fridays and Dr. Cheung on Mondays, Tuesdays, and Thursdays. Family Physician Dr. Elham Rezaeisarlak is accepting new patients and is available Monday through Thursday, delivering dedicated, personalized family care. Dr. Rachel Han, who is fluent in Korean, is available for walk-in patients on Wednesdays and Fridays, broadening access for diverse patient needs. In Edmonton, Imagine Health welcomes Dr. Renata Mishra, a Family Physician with a specialization in women's health. Dr. Mishra is available Monday, Tuesday, and Thursday and accepts referrals for women's health concerns, including IUD insertions.

07:41 EDT AbbVie announces 2025 dividend increase of 5.8% to $1.64 from $1.55 per share - Beginning with the dividend payable in February, 2025. AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.55 per share to $1.64 per share beginning with the dividend payable on February 14, 2025 to shareholders of record as of January 15, 2025. This reflects an increase of approximately 5.8%, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by 310%.

07:35 EDT Hookipa Pharma doses first patients with eseba-vec - HOOKIPA Pharma announced that researchers at Memorial Sloan Kettering Cancer Center, MSKCC, have dosed the first patients in an investigator initiated trial, IIT, of eseba-vec, HOOKIPA's human papillomavirus type 16-targeted investigational immunotherapeutic agent, in patients with minimal residual disease positive HPV-driven head and neck cancer. Malte Peters, Chief Executive Officer of HOOKIPA added, "Eseba-vec was well tolerated and has demonstrated compelling efficacy in combination with pembrolizumab in HPV+ HNSCC. We look forward to building on these promising findings with the expansion into adjuvant care. Our eseba-vec clinical development program in HNSCC continues to advance and we are on track to initiate our pivotal AVALON-1 Phase 2/3 study in the front-line setting for patients with HPV16+ oropharyngeal squamous cell carcinoma in the fourth quarter of 2024. We expect initial safety and efficacy data from the IIT in 2026."

07:34 EDT Intra-Cellular raises FY24 CAPLYTA net product sales view to $665M-$685M - Raised CAPLYTA full year 2024 net product sales guidance range to $665 to $685 million. Narrowed full year 2024 SG&A expense guidance range to $490 to $510 million and full year 2024 R&D expense guidance range to $220 to $230 million.

07:32 EDT MacroGenics announces CEO Koenig to step down - MacroGenics announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process.

07:31 EDT Diversified Energy closes acquisition of East Texas assets - Diversified Energy Company announces the closing of its previously announced acquisition of operated natural gas properties located within eastern Texas from a regional operator. Acquisition Highlights: Total gross purchase price of $69 million before customary purchase price adjustments; $68 million for high working-interest PDP asset package; $1 million for residual interest of retained undeveloped acreage; Acquisition net purchase price of $49 million after customary purchase price adjustments; PDP reserves of ~70 Bcfe and a PDP PV10 of ~$89 million; Current net production of 21 MMcfepd; Estimated NTM Adjusted EBITDA of ~$19 million million; Purchase price multiple of ~3.5x. As previously announced, the net consideration for the Acquisition consists of a combination of the issuance of 2,342,445 new US-dollar denominated ordinary shares to the Seller, and cash consideration of $22 million, drawing from a senior secured bank facility supported by the acquired assets and existing liquidity. The New Shares represent approximately 4.57% of the Company's existing issued share capital. The shares conveyed to the seller are subject to standard regulatory restrictions for a period of six months.

07:31 EDT JinkoSolar sees FY24 module shipments 90.0GW-100.0GW. - The Company expects its annual production capacity for mono wafer, solar cell and solar module to reach 120.0 GW, 95.0 GW and 130.0 GW, respectively, by the end of 2024.

07:29 EDT PTC Therapeutics announces FDA acceptance of Translarna NDA resubmission - PTC Therapeutics announced the U.S. FDA has accepted for review the resubmission of the New Drug Application for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy. As this was an NDA resubmission following a complete response letter to the NDA which was filed over protest in 2016, FDA is not obligated to follow PDUFA review timelines. Thus, an action date has not been provided.

07:27 EDT Neurocrine sees FY24 Ingrezza revenue $2.300B-$2.320B - Sees FY24 Non-GAAP R&D Expense $635M-$655M and Non-GAAP SG&A Expense $825M-$845M.

07:26 EDT Xtract One's Gateway selected to secure Tift County schools - Xtract One Technologies announced their newly-debuted Xtract One Gateway has been selected by Tift County Schools in Tifton, Georgia, to protect school entrances, ensuring a welcoming, streamlined, and secure experience for all individuals entering the buildings.

07:25 EDT CDW boosts dividend by 1% to 62.5c per share - CDW Corporation announced that its Board of Directors has declared a quarterly cash dividend of 62.5c per common share to be paid on December 10 to all stockholders of record as of the close of business on November 25 . This amount represents approximately a 1% t increase over last year's dividend and is aligned with the target of 25 percent of the trailing-twelve-month Non-GAAP net income through September 30 . Future dividends will be subject to Board of Director approval. "Dividends represent an important component of our capital allocation priorities, along with share repurchases, strategic M&A and managing our capital structure." said Albert J. Miralles, chief financial officer, CDW. "Since our IPO in June 2013, our dividend has increased nearly fifteen-fold, with eleven consecutive years of increases, and we have returned approximately $6.9 billion to stockholders through share repurchases and dividends. Our capital allocation strategy has enabled us to deliver value to our stockholders, just as we have delivered value to our customers and partners for 40 years."

07:24 EDT Blueprint Medicines sees FY24 global AYVAKIT net product revenues $475M-$480M - Blueprint Medicines now anticipates approximately $475M-$480M in global AYVAKIT net product revenues in 2024, an increase from the previous range of $435M-$450M. This updated guidance is based on continued growth in patients on therapy, continued favorability in compliance and other performance factors, and stronger than expected performance outside of the U.S. The company continues to expect that full-year operating expenses and cash burn will decline in 2024 as compared to 2023, and that its existing cash, cash equivalents and investments, together with anticipated product revenues, will enable the company to maintain a durable capital position to achieve a self-sustainable financial profile.

07:22 EDT NeueHealth acquires full ownership of Centrum Health - NeueHealth announced that Centrum Health, one of the company's value-driven clinic brands, became a wholly owned subsidiary through the company's acquisition of the remaining 25% equity interest of the business that it did not already own. This action simplifies NeueHealth's corporate structure, streamlining operations to support its ongoing focus on advancing its value-driven, consumer-centric care model.

07:21 EDT ASP Isotopes enters into term sheet with TerraPower - ASP Isotopes announced that it has entered into a term sheet with TerraPower, a nuclear innovation company and advanced nuclear energy developer, related to the construction of a uranium enrichment facility capable of producing High Assay Low-Enriched Uranium, HALEU, and the future supply of HALEU to TerraPower, as a customer of Quantum Leap Energy, QLE.

07:19 EDT Stepan raises quarterly dividend 2.7% to 38.5c per share - The Board of Directors of Stepan Company has approved an increase of 1c per share, or 2.7%, on the quarterly cash dividend on the company's common stock. The dividend of 38.5c per share is payable on December 13 to common stockholders of record on November 29. The increase marks the 57th consecutive year in which the quarterly dividend on the company's common stock has increased.

07:16 EDT Larimar Therapeutics to provide nomlabofusp program update in mid-December - Larimar announced that it will provide a nomlabofusp development program update in mid-December 2024 that will include available safety, PK and frataxin data, as well as available clinical outcomes observations from patients currently receiving a daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the OLE study. An update on enrollment in the OLE study will also be provided.

07:12 EDT Santander Chile raises 2024 ROAE guidance to 18%-19% - The company said, "Given the strong recovery in our results and our current economic estimates for the fourth quarter, we are improving our ROAE guidance for 2024 to 18%-19%. We have upgraded our medium term guidance for ROAEs to 18%-20% and our soft guidance for 2025 indicates a ROAE within this range."

07:06 EDT Humana sees 2025 PDP membership similar to 2024 at 2M

06:59 EDT Stepan appoints Luis Rojo as CEO, Samuel Hinrichsen interim CFO - Stepan announced the appointment of Luis Rojo as president and CEO and as a member of the board of directors, effective immediately. Rojo was most recently the company's VP and CFO, having served in that role since April 2018. Stepan also announced that Samuel Hinrichsen, currently the company's global director of finance, will serve as VP and interim CFO until such time as a permanent replacement is named.

06:34 EDT Estee Lauder names Stephane de La Faverie as CEO, succeeding Fabrizio Freda - The Estee Lauder Companies announced the Board of Directors' appointment of Stephane de La Faverie as its new President and CEO and member of its Board of Directors, effective January 1, 2025. de La Faverie will succeed Fabrizio Freda, who announced his intention to retire earlier this year after more than sixteen years with the company. Freda will support de La Faverie over the next several months to ensure a seamless transition. As President and CEO, de La Faverie will report directly to the company's Board of Directors. Additionally, William Lauder will be stepping down from his current role as Executive Chairman of the company and will remain Chair of the Board of Directors, following the company's upcoming Annual Meeting of Stockholders.

06:20 EDT Clearway Energy raises dividend 1.7% to 42.40c - On October 29, Clearway Energy's Board of Directors declared a quarterly dividend on Class A and Class C common stock of 42.40c per share payable on December 16 to stockholders of record as of December 2.

06:14 EDT Scilex announces successful end of Phase II meeting with FDA - Scilex Holding announced it had a successful end of Phase II meeting with the FDA leading to an agreed path forward to NDA upon completion of Phase III trials for blockbuster product candidate, SP-103 5.4%, a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain associated with muscle spasms. Based on the independent market research conducted by Syneos Health Consulting, with the substantial intent in utilization for SP-103 with peak sales potential projected to reach $1.2B annually in the 6th year post launch. "We are very pleased with the end of Phase II meeting and received a clear path forward to NDA for our blockbuster product candidate, SP-103. SP-103 has the potential to meet our core goal of developing leading pain management therapies to significantly improve the lives of patients for the treatment of chronic neck pain associated with muscle spasms who are seeking new effective treatments. We are looking forward to conducting Phase 3 trials and believe that Scilex is the only company with technology allowing much higher lidocaine concentration than any other topical lidocaine system treatments. Higher concentration of a drug per covered area of skin is important for achieving therapeutic response", said Dmitri Lissin, M.D., Chief Medical Officer of Scilex.

06:13 EDT Grocery Outlet appoints Eric Lindberg as Interim Presidente and CEO - Grocery Outlet Holding announced that Eric Lindberg, current Chairman of the Board, has been appointed Interim President and CEO, effective immediately. Lindberg replaces RJ Sheedy, who has stepped down from his position and resigned from the Company's Board of Directors. The Board has engaged a leading global executive search firm to begin the process of identifying a permanent CEO.With more than three decades of leadership experience at the Company, Lindberg is a Grocery Outlet veteran with a deep knowledge of its operations and strategy. He previously served as CEO or co-CEO from January 2006 through December 2022, during which time he led Grocery Outlet's transformation from a closely-held family-owned business to a sponsor-backed private company, taking on significant outside capital from Berkshire Partners and Hellman & Friedman, and then ultimately to a publicly-traded company in 2019.

06:10 EDT Organon, Shanghai Henlius Biotech: FDA accepts BLA for HLX14 - Shanghai Henlius Biotech and Organon announced that the U.S. FDA has accepted the Biologic License Application for HLX14, an investigational biosimilar of PROLIA/XGEVA. In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to two biosimilar candidates, including HLX14. The agreement covers markets such as the United States, the European Union, and Canada. An exception to the agreement is China.

06:08 EDT nCino to acquire FullCircl for $135M in cash - nCino announced that it has entered into a definitive agreement to acquire FullCircl. FullCircl is a UK-based SaaS platform, built to help financial institutions and regulated companies grow revenue, automate and accelerate onboarding, and improve client lifecycle management by removing regulatory and verification roadblocks. The purchase price for FullCircl is $135M in cash, subject to customary adjustments. $15M of the Purchase Price will be retained by nCino for two years following the closing of the transaction as security for the performance of certain warranties and covenants arising under the purchase agreement. nCino plans to provide an update on the financial impact of this acquisition in connection with its third quarter earnings release.

06:03 EDT UBS sees continuation of market conditions entering Q4 - UBS said: "In the third quarter of 2024 we saw strong client activity against a market backdrop that, while constructive, still exhibited periods of high volatility and dislocation. Entering the fourth quarter, we see a continuation of these market conditions sustained by the prospects of a soft landing in the US economy. However, the macroeconomic outlook in the rest of the world remains clouded. In addition to seasonality, the ongoing geopolitical conflicts and the upcoming US elections are creating uncertainties that are likely to affect investor behavior. In the fourth quarter, we anticipate a mid-single digit decline in net interest income in Global Wealth Management and a low single-digit decline in Personal & Corporate Banking. Non-core and Legacy is expected to generate a quarterly pre-tax loss in line with our earlier guidance. The Group's non-personnel costs are expected to show a seasonal sequential uptick. The Group's quarterly tax rate is expected to be around 35%. Integration-related expenses are expected to be around USD 1.2bn and accretion of PPA effects to contribute around USD 0.5bn to the Group's total revenues."

05:33 EDT DXC Technology, Accelya partner to offer airport retail experience - DXC Technology and Accelya announced they will partner to offer airlines a retail experience and accelerate system integrations for airlines globally. This will enable airlines to modernize operations and introduce new offerings for their customers, ultimately enhancing the traveler's experience.

05:08 EDT Northern Trust appointed custodian of $6B Cadent Gas Pension Scheme - Northern Trust announced it has been appointed by Cadent Gas Pension Trustee as custodian for its public and private assets as well as for performance and SORP reporting for its $6B defined benefit scheme. Cadent Gas Pension Scheme appointed Northern Trust following a detailed due diligence exercise, managed independently.